PEPN2411; DT2216 (NSC#850950, IND# 170973) in combination with irinotecan for children, adolescents and young adults with relapsed or refractory solid tumors: A Phase 1 study with Phase 2 feasibility cohort for fibrolamellar carcinoma
Primary Aims 1. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of DT2216 in combination with intravenous irinotecan in patients with recurrent/refractory solid tumors. 2. To define and describe the toxicities of DT2216 in combination with irinotecan administered on this schedule in patients with recurrent/refractory solid tumors and patients with fibrolamellar carcinoma (FLC). 3. To characterize the pharmacokinetics of DT2216 in combination with irinotecan in patients with recurrent/refractory solid tumors and patients with fibrolamellar carcinoma (FLC). 4. To preliminarily define antitumor activity of DT2216 in combination with irinotecan in patients with recurrent/refractory solid tumors (within the confines of a Phase 1 study) and in patients with recurrent/refractory FLC.
• Phase 1: Relapsed & refractory solid tumor. Age: Patients between ≥ 1 year and ≤ 21 years of age at the time of study. Diagnosis: Patients with recurrent/refractory solid tumors excluding primary central nervous system tumors. Disease Status: Patients must have either measurable or evaluable disease.
• Phase 2: Fibrolamelar carcinoma. Age: Patients between ≥ 1 year and ≤ 39 years of age at the time of study enrollment. Diagnosis: Patients with (FLC), which must include genomic confirmation of the DNAJB1:PRKACA fusion performed at a CLIA-certified laboratory. Disease Status: Patients must have measurable disease.
• Pregnant or breast-feeding women.
• Concommitant meds: Corticosteroids, Investigational Drugs, Anti-cancer Agents, Anti-GVHD agents post-transplant, CYP-450 Interactions.
• Patients with lymphoma.
• Patients who have an uncontrolled infection.
Bone, Joint & Muscle, Cancer, Children's Health